Increased MALAT1 expression contributes to cisplatin resistance in non-small cell lung cancer

Cisplatin-based chemotherapy is commonly used for the clinical treatment of patients with non-small cell lung cancer (NSCLC). However, the anti-tumor efficacy of cisplatin is limited by poor clinical response and the development of chemoresistance. At present, the underlying mechanism for cisplatin...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Yong, Li, Guanlong, Zhang, Xin, Dai, Fangfang, Zhang, Rongxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6144744/
https://www.ncbi.nlm.nih.gov/pubmed/30250547
http://dx.doi.org/10.3892/ol.2018.9293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6144744/
https://www.ncbi.nlm.nih.gov/pubmed/30250547
http://dx.doi.org/10.3892/ol.2018.9293

Ejemplares similares